Key result
The RT-LAMP-coupled CRISPR–Cas12 assay yielded 96% sensitivity, 100% specificity, and 97% agreement for HCV RNA detection compared to the reference method.
Why the study?
Identifying individuals with current hepatitis C remains challenging, particularly in resource-limited settings with limited access to molecular testing.
Does the RT-LAMP-coupled CRISPR-Cas12 assay accurately detect HCV RNA compared to the reference method in clinical samples?
Population
Clinical samples from individuals infected with HCV, HIV, or HBV, or healthy donors
Comparison
RT-LAMP-coupled CRISPR-Cas12 assay vs Roche COBAS AmpliPrep/COBAS TaqMan HCV Test
Design
Diagnostic validation study
Authors
Loading...
May enable point-of-care HCV RNA testing where molecular assays are unavailable; leaves open need for field validation before clinical adoption.
Does the RT-LAMP-coupled CRISPR-Cas12 assay accurately detect HCV RNA compared to the reference method in clinical samples?
The RT-LAMP-coupled CRISPR-Cas12 assay provides a highly sensitive and specific point-of-care test for rapid HCV detection in resource-limited settings.
Kham-Kjing et al. (2022) studied Hepatitis C virus (HCV) infection. RT-LAMP-coupled CRISPR–Cas12 assay vs. Roche COBAS AmpliPrep/COBAS TaqMan HCV Test was evaluated on Diagnostic sensitivity, specificity, and agreement for HCV RNA detection. The RT-LAMP-coupled CRISPR–Cas12 assay yielded 96% sensitivity, 100% specificity, and 97% agreement for HCV RNA detection compared to the reference method.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: